Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alx Oncology Holdings Inc
(NQ:
ALXO
)
1.290
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.290
Bid (Size)
1.230 (2)
Ask (Size)
1.290 (2)
Prev. Close
1.290
Today's Range
1.290 - 1.290
52wk Range
1.190 - 17.82
Shares Outstanding
40,869,135
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
November 14, 2024
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 07, 2024
From
ALX Oncology
Via
GlobeNewswire
Performance
YTD
-91.13%
-91.13%
1 Month
-14.00%
-14.00%
3 Month
-44.64%
-44.64%
6 Month
-91.22%
-91.22%
1 Year
-85.99%
-85.99%
More News
Read More
ALX Oncology Announces November Investor Conference Participation
November 04, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
November 01, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 04, 2024
From
ALX Oncology
Via
GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
August 27, 2024
Via
Benzinga
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
August 09, 2024
Via
InvestorPlace
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 06, 2024
From
ALX Oncology
Via
GlobeNewswire
Crude Oil Moves Lower; Moderna Shares Plunge
August 01, 2024
Via
Benzinga
Exposures
Fossil Fuels
Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
August 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
August 01, 2024
Via
Benzinga
Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
August 01, 2024
Via
Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
August 01, 2024
Via
Benzinga
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
May 29, 2024
From
ALX Oncology
Via
GlobeNewswire
ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 07, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
April 30, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 24, 2024
From
ALX Oncology
Via
GlobeNewswire
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
April 17, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.